Share Name Share Symbol Market Type Share ISIN Share Description
Astrazeneca Plc LSE:AZN London Ordinary Share GB0009895292 ORD SHS $0.25
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  42.00 0.53% 7,922.00 7,921.00 7,924.00 7,936.00 7,805.00 7,805.00 104,980 08:41:39
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 18,386.4 1,167.2 77.7 99.9 103,929

EU Agrees to Buy Potential Sanofi, GSK Covid-19 Vaccine -- Update

18/09/2020 1:08pm

Dow Jones News

Astrazeneca (LSE:AZN)
Historical Stock Chart

From Aug 2020 to Oct 2020

Click Here for more Astrazeneca Charts.

-The European Commission has agreed to buy Sanofi and GSK's potential Covid-19 vaccine

-EU member states will be able to purchase up to 300 million doses of the vaccine

-Sanofi and GSK aim to have the vaccine available by the second half of 2021


By Mauro Orru and Giulia Petroni


The European Commission said Friday that it has signed a contract with Sanofi SA and GlaxoSmithKline PLC to secure up to 300 million doses of their potential Covid-19 vaccine.

The commission, the EU's executive arm, didn't disclose financial details but said the contract marks the second deal the EU has struck for the supply of vaccines against coronavirus, following a deal it already signed with British drug maker AstraZeneca PLC.

"Agreements with other companies will be concluded soon and build a diversified portfolio of promising vaccines, based on various types of technologies, increasing our chances to find an effective remedy against the virus," European Commission President Ursula von der Leyen said.

The commission added that it will finance part of the upfront costs faced by the producers as part of its strategy to accelerate the development and deployment of Covid-19 vaccines. The funding will be considered as "a down-payment" on the vaccines that will be purchased by member states.

Sanofi and GSK aim to have the vaccine available by the second half of 2021, after starting a Phase 1 and 2 study in September, with a Phase 3 study by the end of 2020.

In regards to regulatory processes, the commission said any vaccine will have to undergo assessments by the European Medicines Agency according to the EU market authorization procedure.


Write to Mauro Orru at and Giulia Petroni at


(END) Dow Jones Newswires

September 18, 2020 07:53 ET (11:53 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.

1 Year Astrazeneca Chart

1 Year Astrazeneca Chart

1 Month Astrazeneca Chart

1 Month Astrazeneca Chart
ADVFN Advertorial
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20201029 08:56:40